Hugel has launched Thechaum Signature, a hyaluronic acid filler formulated with reduced crosslinker density compared to standard HA offerings. The approach aims to deliver a softer, more malleable product that maintains longevity while improving natural feel and ease of injection—a rheological trade-off that appeals to practitioners seeking less resistance during placement and patients prioritizing a subtle aesthetic.
Injectables
Hugel Debuts Thechaum Signature with Reduced Crosslinker
Hugel's new HA filler uses less crosslinker. What the rheology shift means for your practice.

1-YEAR MOVE
ABBV
▲11.6%
| Ticker | Company | 1-year change |
|---|---|---|
| ABBV | AbbVie (Allergan Aesthetics) | +11.6% |